This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The most desired information doctors now want is about patient assistance programs, with 49% saying they want pharma reps to provide that information. I reached out to three HCP marketing people at different pharmacompanies and asked them for their feedback on this survey. Where to start? Here are some options.
IN BRIEF: Pharmacompanies have been posting jobs on LinkedIn almost every day. While most offices remain closed pharma is preparing for the launch of new products and has to have the infrastructure to ensure a successful launch. Yet, too many pharmacompanies don’t get social media snapshots of what’s being said.
After a year of pandemic-delayed medical tr eatments, doctors are seeing more cases of advanced illnesses. J&J did the right thing by asking for help from other pharmacompanies, but as I thought, COVID vaccines are a huge source of income, not helping the public defeat this pandemic. Now that people are returning.
The politics of working with a major pharmacompany can be a difficult challenge. Just when you think you have broken through, pharma marketing, people rotate, leave, or get promoted, and the process is pushed back three or four steps. The other change that agencies need to push is the idea that product websites are alive.
Digital channels play a far greater role in communication between pharmacompanies and healthcare professionals than before the pandemic. . FINDING : Doctors across the globe report a significant increase in the consumption of online medical content compared to pre-pandemic levels. Medscape Detailed Findings.
Apple, with its new privacy requirements, is challenging app developers and brands while Facebook cries fowl. So should pharma be in the app business? First there is the cost of developing an app. But at the same time, 93% of doctors believe mHealth apps can improve patients’ health. Blood sugar or diabetes tools.
As HCPs get more digitally savvy, pharma marketers should understand that engaging physicians through channels and time of their preference with content relevant to the individual customer. FutureReadyHealthcare listed the following key findings: 77% of HCPs use digital channels primarily for personal learning and development.
They expect and want more from HCPs and pharmacompanies. 5ive: People are interacting with their doctors in new ways. There is no longer a need to go to the doctor to ask for an Rx renewal. Omnichannel marketing, for example, depends on the audience size and the message development.
At the same time, experts are saying developers in the field need to double down on securing clinical data to allow for its continued maturation. Companies are testing the use of digital platforms along with pharmacological treatments. Securing reimbursement for digital therapeutics also continues to impede its uptake.
Pharmacompanies have been investing deeply into digital advertising but vastly under measuring customer engagement and other metrics. Pharma marketers spend countless hours developing PowerPoints and getting approval for tactics, but they need specific listening metrics to pivot quickly if their plans aren’t effective.
2wo: Telehealth will find use among patients because of convenience – No need to go to the doctor to ask for an Rx renewal and, in some cases, a new Rx. 3hree: Pharma will increase its spending in digital, but a lot of the money will be wasted. Digital, within healthcare, is used differently by online health seekers.
But do doctors trust the system? consumers’ trust in pharma is low, despite the industry’s contributions to ending the pandemic: Only 15% of U.S. consumers say they trust pharmacompanies more than they did before the COVID-19 pandemic, according to Accenture’s 2021 survey.
Many doctors also became upset at the idea of telling Alzheimer’s patients that the drug didn’t work. 4our: Biogen needs to decide “who they are” Are they a big pharmacompany that competes in several areas or biotech that develops drugs for specific markets?
Diabetes patients are having a vibrant discussion about the new “weight loss” drugs and asking many questions about their use and side effects, which pharma seems to be ignoring in their product website’s content. DTC managers are often surprised by the results. DTC marketers seem to ignore this data.
As we have seen over the past few years, Pharmacompanies are a business, a regulated business, but still a business. To portray patients, mindless people who blindly believe DTC TV ads and rush to their doctor to ask for a product are inaccurate. I just finished watching a Zoom call where people evaluated a new DTC spot.
Doctors using telemedicine software are not sure of its value to patients and believe telehealth may pose risks. They have even developed an app that can be used on a patient’s smartphone or tablet to make them accessible. The hype around telehealth has followed a projected pattern.
Pharmacompanies are increasing digital budgets, but they are wasting too much money because of internal staffing issues and inexperience with online marketing. Pharma DTC marketers should develop personas for their target audience that tells us who they are like: 1ne: Where do they go for medical information online?
The global pandemic has caused pharmacompanies to invest in digital marketing, as healthcare systems across the world adapt to strict lockdown rules. Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communications. This is an increase in 14.2%
Pharma, PBM, and health insurance CEOs earn hundreds of millions of dollars to do one thing; make their companies a lot of money. Pfizer is even taking a step further saying they no longer need a partner in developing future vaccines. Rising costs are unsustainable despite the talk about virtual visits.
During the course of the webinar, Keefer explained how specialty sites, with deep knowledge on one or certain groups of Rare Diseases, are crucial for further progress in drug development to progress the number of treatments available to Rare Disease patients and to provide support to those individuals. The potential to leverage genomic data.
There is a HUGE opportunity for pharmacompanies to help sort through all the misinformation and talk to patients as people, not sales targets. It’s reasonable to believe that, because of the COVID surge, people are once again putting off some treatments and canceling appointments with their doctors.
While the consolidation of agencies may be a priority for some pharmacompanies a good digital agency can add a lot of value. When I was in charge of the Cialis online launch, I developed a website for our agencies to share insights, timelines, and creatives. Now about the agency integration.
Meanwhile, field teams’ promotional content is still reflective of the pre-COVID paradigm, and Noel says companies need to rethink what content messages will be beneficial for HCPs. Reps should not just be pushing product messages – they should be asking doctors what they need right now and how they can help.”.
COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right circumstances – but there is much to do to ensure this progress is not lost, said speakers at WIRED Health 2021, including the CEOs of BioNTech and BenevolentAI. . BioNTech seeks “new kind of pharmacompany”.
Going from the vital activity of patient engagement to the more encompassing state of patient centricity requires big steps in the evolution of new-drug discovery, development, and delivery. It is drug developers, patients, advocates, and caregivers in active conversations—more likely to involve clean sheets of paper than prepared scripts.
The avid blogger and passionate advocate retired from his R&D role four years ago to focus on his own health, and now works full time on making sure the patient voice is “in the room” when pharmacompanies make decisions. We meet once a month throughout the development cycle to provide feedback. Winding road. “My
Smaller biotechs that are developing new drugs usually don’t have the resources to take new drugs to market. The venture capitalists funding them are looking for a big payday when a pharmacompany acquires them. The cost is estimated to be in the billions.
The shift to virtual alone has already had a profound impact on all conference stakeholders: medical societies themselves, doctors, patients, commercial partners, and professional conference organisers (PCOs). Doctors want a choice. Part 2 will assess possible scenarios for 2022 and beyond. Lessons learnt 2020-2021. yes; and 15.7%
to develop an intra-uterine sensor system and generate clinical data that could be used for European approval. Developed by the government and delivered by the British Business Bank, the Future Fund supports high potential innovative businesses in the UK currently affected by COVID-19.
India’s Dr Reddy’s Laboratories has joined the growing list of pharmacompanies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum. The two drugs were developed by medical cannabis pioneer GW Pharma, which was acquired by Jazz last year.
billion for research into the disease, which represents a fraction of the overall spend dedicated to learning more about cancer’s development in humans and in the creation of new treatments. An area that offers hope to accelerate an understanding of cancer and speed up drug development is artificial intelligence. Patient focus.
These same changes can also lower the chances of developing heart disease and some cancers. Where does pharma’s responsibility in this area? Most people who go to pharma product websites already have a health problem and they are looking for solutions. Prediabetes and type 2 diabetes are largely preventable.
It was a joke, one MP said to the BBC – a jibe about a colleague eating a sandwich during the meeting – and wasn’t intended in any way to be critical of pharmacompanies or a triumphalist take on the UK’s successful vaccine rollout. " But he’s wrong.
A study of people who consulted a doctor after an abnormal pulse was detected by their device suggests it could lead to false positives that mean unnecessary healthcare visits, according to the team from the Mayo Clinic.
Ask a diabetes patient which pharmacompany is the leader in diabetes therapy? You’re likely to hear a whole range of answers because no company has moved forward with content that ensures they become the standard for online diabetes patients. 2wo: What’s the relationship between TV DTC and a product website?
(New York Times ) If you spend any time reading pharma PR releases, you’ll see over and over again corporate managements stressing the importance of the shareholder. When a new drug is derailed the first thing that pops out is the effect on the company’s stock price, not patients.
The companies are based on opposite sides of the Atlantic – Moderna was founded in Massachusetts in 2010 under the name ModeRNA Therapeutics by a team of investors two years after BioNTech began operating from a small lab in Mainz, Germany. They are very good doctors, scientists and entrepreneurs.
There is hope among researchers and drug developers that hepatitis C treatment innovations can be leveraged to find a cure for hepatitis B. This may be due to lack of access or problems preventing patients from visiting doctors such as mistrust of healthcare systems or mental health issues. DOWNLOAD THE FULL ARTICLE HERE.
The webinar discussed findings of exclusive surveys showing the continuing medical education (CME) needs of doctors and shone a light on where physicians are going for their learning needs amid the COVID-19 pandemic. He said: “They do have a responsibility towards educating healthcare professionals on the correct use of their drugs.”.
As it turned out, pharmaphorum’s launch coincided with digital’s early permeation of the healthcare industry. “[Digital] was becoming an increasing feature of our content, whether we were talking about what patients were doing in the industry, what tech companies were coming in, et cetera. Healthcare’s early digital transformation.
Francisco Partners is picking up a range of databases and analytics tools – including Health Insights, MarketScan, Clinical Development, Social Programme Management, Micromedex and other imaging and radiology tools – for an undisclosed sum estimated to be in the region of $1 billion.
With COVID-19 vaccines and therapeutics developed in rapid time, Ben Hargreaves investigates why this has not been the case with the creation of a treatment for Long COVID. Once the scale of the threat was understood, the pharmaceutical industry reacted with a rapidity and agility that allowed vaccines to be developed at a record rate.
“The cost of developing a new drug is extortionately high,” said Landray, adding that a very large proportion of those costs is in phase 3, and that means many promising therapies may never be taken forward by pharmacompanies.
Digital data collection, utilisation of real-word data and patient-centric thinking will all contribute to the rapid development of a new healthcare landscape, says Debiopharm Innovation Fund’s Tanja Dowe. The time of individuals relying entirely on face-to-face interaction with their doctors is long past.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content